Efferon secures €2.5M to grow blood purification platform

Biotech company Efferon has raised €2.5 million in a seed funding round led by private investors from the DACH region to support the European commercial expansion of Efferon LPS, its hemoadsorption device approved for the treatment of sepsis and septic shock. Efferon develops multimodal hemoadsorption therapeutic devices designed to remove endotoxins and inflammatory mediators directly from the bloodstream. The company’s product portfolio includes Efferon LPS, a hemoadsorption cartridge combinin